

Editorial

I am very pleased to introduce Dr. Morgan L. Beatty as Associate Editor, Pharmaceutical Technology. With the growing scope and increased manuscript flow of *Pharmaceutical Research*, it became more and more difficult to pay justice to each scientific field represented in the journal. According to the long-range goals for the journal's development, I began to contact some of the sections of the AAPS to nominate Associate Editors. It is particularly fortunate that Morgan Beatty, who currently also serves as the Section Chair, Pharmaceutical Technology, was the first Associate Editor to be proposed, and I am very grateful that he has accepted this important, but also laborious, task. He will be able to better define the criteria for publication of papers in his specialty field, monitor the representation of Pharmaceutical Technology among the other areas in the journal, and introduce review topics on relevant issues. Also, Dr. Beatty, as a scientist from the pharmaceutical industry, counterbalances the rather heavy academic representation of the Board. If you have specific ideas for the further development of Pharmaceutical Technology in the journal and the AAPS, please contact Dr. Beatty directly.

The major goal of *Pharmaceutical Research* remains unchanged: to attract the best research papers in all fields related to pharmaceutical-biomedical research from around the world. At the same time, this journal should also function as a publication forum for the important research activities of AAPS members. During the rapid growth phase, both objectives can be accommodated by increasing the page volume up to a certain limit. However, I am convinced that members of the AAPS alone currently produce many more publications than can be accommodated in one journal. With

a steadily increasing manuscript flow, expected to continue over the next few years, I foresee a time when the capacity of *Pharmaceutical Research* will become saturated and the two objectives will be on a collision course. At that time, the AAPS and specifically its individual sections should be planning on the development of specialty journals to supplement *Pharmaceutical Research*. Clearly, this time has not yet arrived; however, for Pharmaceutical Technology, Dr. Morgan L. Beatty can begin to systematically monitor the publication needs of this specialty to the benefit of all. I anticipate that additional Associate Editors will join soon.

All manuscripts except those from Europe, should continue to be sent to the San Francisco editorial office, but authors can state if their manuscript falls into the Pharmaceutical Technology category. As a reminder to referees, Editorial Advisors, and Editors, the current policy for acceptance of papers is based on a dual evaluation of scientific content and priority. All research manuscripts must receive at least average priority to be considered for publication, but full-length research articles must be assigned above-average priority by at least one referee. The Editors may occasionally waive these requirements, if the referee's evaluations indicate that the paper contains interesting features or can be sufficiently improved. Page limits given in the Instructions to Authors should be honored whenever possible; however, it is again a prerogative of the Editors to waive the page limit if the subject matter requires it.

Wolfgang Sadée
Editor